BioWorld

May 20, 2004

Phase III Antegren Data Show Benefit For Crohn's Continues

Offering new data for Antegren against Crohn's disease, Biogen Idec Inc. said it will file for approval in the European Union but is conducting another study in the U.S. before seeking approval here. (BioWorld Today) Read More

Senate Passes BioShield In 99-0 Vote; $5.6B Slated For Industry

Two Companies Spun Out Of Seattle Incubator Organization

J&J, Centocor Acquiring Egea For Protein Design Technology

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...